Presents Research on Bacillus coagulans IDCC 1201 at International Microbiome Conference Clinical Study Demonstrates Improved Sleep Efficiency, Longer Total Sleep Time, and Enhanced Sleep Continuity ILDONG Bioscience (CEO: Ban Oh-hyun), the health functional food subsidiary of the ILDONG Pharmaceutical Group, has received the Best Poster Award at the International Scientific Conference on Probiotics, Prebiotics, Gut Microbiota and Health (IPC 2026) for its research on a probiotic strain that improves sleep quality. IPC is a globally recognized scientific conference focused on the relationship between the microbiome and human health. The conference provides a platform for researchers and industry experts to share the latest scientific findings and technological advancements in probiotics, prebiotics, gut microbiota, and related fields. This year's event was held in Kraków, Poland, from June 22 to 24, 2026. At the conference, ILDONG Bioscience presented a poster highlighting the efficacy and safety of its proprietary probiotic strain, Bacillus coagulans IDCC 1201, in improving sleep quality. The study attracted significant attention from researchers and industry professionals and was recognized with the conference's Best Poster Award. The clinical trial was conducted as a randomized, double-blind, placebo-controlled study involving adults experiencing sleep disturbances. Participants consumed IDCC 1201 for four weeks, and researchers evaluated its effects using both objective sleep measurements and subjective assessments of sleep quality. According to the study, polysomnography (PSG) demonstrated significant physiological improvements after supplementation with IDCC 1201. Sleep efficiency increased by more than 13%, while total sleep time increased by approximately 50 minutes, indicating that participants spent a greater proportion of their time in bed actually sleeping. The study also found significant reductions in wake after sleep onset (WASO) and total wake time, suggesting that IDCC 1201 helped maintain more continuous and stable sleep throughout the night. Subjective sleep quality was evaluated using the Pittsburgh Sleep Quality Index (PSQI), which assesses multiple aspects of sleep, including sleep duration, sleep latency, sleep quality, sleep efficiency, sleep disturbances, use of sleep medication, and daytime dysfunction. Participants receiving IDCC 1201 showed statistically significant improvements across these measures compared with the placebo group. "We are honored that our research has been recognized at a prestigious international scientific conference," said an ILDONG Bioscience representative. "This award demonstrates the global competitiveness of our R&D capabilities and proprietary probiotic technologies. We will continue to accelerate follow-up research and commercialization of IDCC 1201." Established in 2016, ILDONG Bioscience specializes in probiotics and health functional ingredients. The company possesses a proprietary strain library of more than 5,000 microbial strains, supported by numerous patents and proprietary technologies. Leveraging its advanced research capabilities, ILDONG Bioscience has developed a wide range of probiotics and postbiotics targeting areas such as gut health, skin health and immunity, cholesterol management, body fat reduction, and sleep health. Supported by one of the industry's leading manufacturing infrastructures, the company actively provides functional ingredients, develops finished products, offers CDMO (Contract Development and Manufacturing Organization) services, and supplies probiotic ingredients to global partners.

Ildong Pharmaceutical Group Pursues Partnering Opportunities for GLP-1 Obesity Treatment and Other Pipelines at BIO USA 2026 Ildong Pharmaceutical Group is participating in BIO USA 2026, where it will showcase its new drug pipelines and engage in business development activities, including partnering meetings with global pharmaceutical and biotechnology companies. BIO USA is the world's largest biotechnology and pharmaceutical networking event, bringing together industry leaders for technology exchange and business collaboration. This year's conference will be held in San Diego, California, from June 22 to 25. During the event, Ildong Pharmaceutical Group plans to explore collaboration opportunities related to drug development and commercialization, including research and development partnerships, licensing-out agreements, and open innovation initiatives with numerous international companies and global partners. Ildong Pharmaceutical will hold partnering meetings focused on ID110521156, a GLP-1 receptor agonist (GLP-1 RA) being developed for obesity and diabetes treatment, as well as padoprazan, a potassium-competitive acid blocker (P-CAB) currently under development for the treatment of peptic ulcer-related diseases. ID110521156 is an orally administered small-molecule synthetic drug candidate that offers several advantages over existing peptide-based injectable therapies, including differentiated pharmacological properties, manufacturing efficiency, cost-effectiveness, and patient convenience. Notably, the compound maintains therapeutically effective blood concentrations for more than 18 hours without accumulation in the body, making it well suited for once-daily, long-term oral administration. Previously, ID110521156 demonstrated body weight reduction of up to 13.8% over four weeks in a Phase 1 clinical trial. The candidate also exhibited a favorable safety profile, with no serious adverse events reported, including the gastrointestinal disorders and hepatotoxicity commonly associated with existing therapies. Based on the Phase 1 clinical data, Ildong Pharmaceutical plans to continue discussions with existing and prospective global partners regarding commercialization opportunities, including potential licensing-out agreements. Padoprazan, a P-CAB therapy, is being co-developed with Daewon Pharmaceutical. Daewon Pharmaceutical is currently conducting a Phase 3 clinical trial in Korea to evaluate the efficacy and safety of padoprazan in patients with erosive and non-erosive gastroesophageal reflux disease (GERD). Leveraging its overseas rights to padoprazan, Ildong Pharmaceutical is pursuing licensing-out opportunities in international markets. The company is also considering follow-up strategies, including the launch of the product under its own brand upon completion of domestic development. Idience, Ildong Pharmaceutical Group's oncology-focused R&D affiliate, will present its oncology pipeline, including: Venadaparib, a PARP inhibitor ID12241, a pan-KRAS inhibitor A dual-payload antibody-drug conjugate (ADC) platform Venadaparib has received both Orphan Drug Designation and Fast Track Designation from the U.S. Food and Drug Administration (FDA). The candidate is currently being evaluated in multiple clinical studies, including a Phase 2a combination therapy trial for gastric cancer in Korea and the United States. Last year, Idience signed a licensing-out agreement valued at approximately KRW 70 billion covering the Eurasian Economic Union (EAEU) and Gulf Cooperation Council (GCC) regions. An official from Ildong Pharmaceutical Group stated, “In addition to our pre-arranged partnering meetings for each affiliate and pipeline, we plan to actively engage in networking activities aimed at generating global business opportunities, including commercialization discussions related to our novel drug candidates.”  

Ildong Bioscience Seeks to Expand Global Presence at Vitafoods Europe Functional Probiotics and Postbiotics, Including U.S. GRAS-Certified Ingredients, Draw Strong Interest Ildong Bioscience, the health functional food subsidiary of the Ildong Pharmaceutical Group, announced on May 11 that it participated in Vitafoods Europe 2026, showcasing its business capabilities and functional ingredients while exploring opportunities to expand its global market presence. Vitafoods Europe is the largest healthcare, nutraceutical, and functional food exhibition in Europe. This year’s event was held in Barcelona, Spain, from May 5 to 7. During the exhibition, Ildong Bioscience highlighted its competitive strengths in the probiotics and postbiotics sectors, featuring its portfolio of functional ingredients as well as proprietary technologies such as its advanced quadruple-coating process. The company also held partnering meetings with numerous global companies to identify potential collaborators and explore strategic business partnerships for overseas market expansion. An Ildong Bioscience representative stated, “Our portfolio of more than 20 ingredients that have achieved U.S. GRAS (Generally Recognized as Safe) status, along with Halal- and Kosher-certified probiotic ingredients tailored to the needs of global markets, attracted significant attention from visitors.” The representative added, “In addition to our steadily growing business in Asia and North America, we are expanding our export footprint into European countries such as Spain and Greece. Based on localized market strategies, we plan to broaden our customer base and diversify our business portfolio.” Founded in 2016, Ildong Bioscience is a health functional food company specializing in lactic acid bacteria and probiotic-based solutions. The company possesses strong competitive advantages, including a database of more than 5,000 microbial strains, numerous patents, and proprietary technologies. Leveraging its in-house technologies, Ildong Bioscience develops and supplies a wide range of probiotics and postbiotics related to gut health, skin immunity, cholesterol management, body fat reduction, and sleep health. The company also actively operates businesses in functional ingredient and product development, Contract Development and Manufacturing Organization (CDMO) services, and ingredient supply, supported by one of the industry's most advanced manufacturing infrastructures.    

Ildong Pharmaceutical Hosts Beauty Class for PDRN Functional Cosmetic ‘REJUNIQ’ Influencers from Diverse Fields Gather to Share Experiences and Product Ideas Ildong Pharmaceutical (Co-CEOs: Paul Woongsup Yun and Chae Joon Lee) held a “REJUNIQ Beauty Class” event featuring its PDRN-based functional cosmetic product, REJUNIQ PDRN Rejuvenating & Repair Cream (hereinafter referred to as “REJUNIQ”). The event took place on April 22 at the company’s headquarters in Seocho-gu, Seoul, and was attended by approximately 20 influencers from a wide range of professions, including models, announcers, professional golfers, and marketing specialists. According to the company, the event provided an opportunity for participants to personally experience REJUNIQ while sharing skincare tips, lifestyle-based product usage ideas, and beauty know-how. As a pharmacy-exclusive cosmetic brand that reflects the identity and philosophy of a pharmaceutical company, the event went beyond a simple product trial. Instead, it focused on allowing participants to experience and connect with the product quality and brand value of REJUNIQ. REJUNIQ is a newly launched functional skincare product from Ildong Pharmaceutical designed to make the increasingly popular skincare ingredient PDRN (Poly Deoxy Ribo Nucleotide) readily accessible through local pharmacies. The product contains 15,000 ppm of Sodium DNA, a PDRN ingredient derived from Alaskan salmon, along with a variety of skin-enhancing ingredients, including: EGF (Epidermal Growth Factor) Bakuchiol, a plant-based retinol alternative Cica (Centella Asiatica Leaf Extract) In addition, the formula includes: Panthenol 11 types of Hyaluronic Acid for skin hydration Niacinamide, which helps improve skin brightness Adenosine, known for its anti-aging benefits, including wrinkle improvement and enhanced skin elasticity As part of the event, Ildong Pharmaceutical also conducted a pre-launch testing program using samples from upcoming products in the REJUNIQ Series. The company plans to utilize consumer feedback gathered during the testing process—including opinions on products currently in development—to further enhance product quality and refine its marketing strategies. Kim Seok Tae, Head of the OTC Division at Ildong Pharmaceutical, stated, “REJUNIQ was developed with a sufficiently high concentration of PDRN, taking into account both user benefits and accessibility, and has been launched as a functional cosmetic product distributed through pharmacies. Through continuous communication with consumers and diverse marketing campaigns, we aim to establish REJUNIQ as a brand that delivers a differentiated customer experience.”

Ildong Pharmaceutical Expands 'Droptop' Hyperlipidemia Treatment into 3 Additional ASEAN Countries Building Cooperative Relationship with Indonesia's Kalbe Group Across 8 Southeast Asian Markets Ildong Pharmaceutical (Co-CEOs: Paul Woongsup Yun and Chae Joon Lee) announced on the 14th that it has signed an additional agreement with its Indonesian partner Kalbe Farma to expand the supply territory of its 'Droptop' product in order to broaden its presence in Southeast Asia. Droptop is a combination therapy for dyslipidemia that combines rosuvastatin, a statin-class drug that inhibits cholesterol synthesis in the body, with ezetimibe, which suppresses the absorption of cholesterol in the body. Ildong Pharmaceutical has recently signed an agreement with Kalbe International Pte. Ltd. — the distribution subsidiary of Kalbe Farma — to add three additional ASEAN (Association of Southeast Asian Nations) countries to the Droptop supply scope. With this agreement, Ildong Pharmaceutical has now established a cooperative relationship with the Kalbe Group across a total of eight Southeast Asian countries in the dyslipidemia treatment market, including Indonesia and neighboring countries that were previously covered under the existing supply territory. Ildong Pharmaceutical signed a partnership agreement with Kalbe Farma — Indonesia's leading pharmaceutical company — in 2020 for the supply of Droptop, and has been exporting the product since 2023 following regulatory approval and launch procedures. Droptop is marketed locally under the brand name 'Rozet', recording a compound annual growth rate (CAGR) of approximately 130% over the three years since its launch, and currently holds the number one market share in the dyslipidemia combination therapy segment in Indonesia. Building on its partnership with the Kalbe Group, Ildong Pharmaceutical plans to sequentially pursue product approval and launch procedures in the newly contracted countries, while accelerating Droptop's market establishment through locally tailored marketing and distribution strategies. A representative of Ildong Pharmaceutical stated, "Through this agreement, Droptop can now enter most ASEAN member states, which serve as a central pillar of the Southeast Asian economy. We plan to continuously expand the market scope and product lineup together with the Kalbe Group."